Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckstein, Rena, Kuruvilla, John, Chua, Neil, Lee, Christina, Macdonald, David A, Al-Tourah, Abdulwahab J, Foo, Alison H, Walsh, Wendy, Ivy, S Percy, Crump, Michael, Eisenhauer, Elizabeth A
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Original Article: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082168/
https://www.ncbi.nlm.nih.gov/pubmed/21463120
http://dx.doi.org/10.3109/10428194.2011.555892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082168/
https://www.ncbi.nlm.nih.gov/pubmed/21463120
http://dx.doi.org/10.3109/10428194.2011.555892

Ejemplares similares